2cureX AB (2CUREX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 30 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.06%

Debt Equity

-5.10

Return on Equity

-3,081.80%

Price to Book

30.25

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2023)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-58.5%

6 Months

-74.78%

1 Year

118.42%

2 Years

-51.41%

3 Years

-88.8%

4 Years

-93.11%

5 Years

-94.11%

2cureX AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.19%

EBIT Growth (5y)

-163.65%

EBIT to Interest (avg)

-27.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

38.28

EV to EBIT

-0.89

EV to EBITDA

-0.89

EV to Capital Employed

-7.42

EV to Sales

33.18

PEG Ratio

Dividend Yield

0.05%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-3081.80%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -100.00% vs 0.00% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 51.96% vs -24.39% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.90",
          "val2": "-10.00",
          "chgp": "11.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.90",
          "val2": "-10.20",
          "chgp": "51.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-115,471.30%",
          "chgp": "11,547.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 100.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 85.39% vs -3.36% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.20",
          "val2": "-37.20",
          "chgp": "86.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.50",
          "val2": "-30.80",
          "chgp": "85.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-241,851.60%",
          "chgp": "24,185.16%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Dec'23

Sep'23

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-8.90

-10.00

11.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.90

-10.20

51.96%

Operating Profit Margin (Excl OI)

0.00%

-115,471.30%

11,547.13%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2023 is -100.00% vs 0.00% in Sep 2023

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is 51.96% vs -24.39% in Sep 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

0.20

-100.00%

Operating Profit (PBDIT) excl Other Income

-5.20

-37.20

86.02%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.50

-30.80

85.39%

Operating Profit Margin (Excl OI)

0.00%

-241,851.60%

24,185.16%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 85.39% vs -3.36% in Dec 2023

All Annual Results

Company CV

About 2cureX AB

2cureX AB

Pharmaceuticals & Biotechnology

2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.

Company Coordinates

Company Details

C/o Mazars SET Revisionsbyra AB, Box 159 , LANDSKRONA None : 261 22

Tel:

https://www.2curex.com/

Registrar Details